2024 Revenues ($USD) : $6.39B

Privately-owned Servier posted strong performance in its 2023/2024 fiscal year, with revenue climbing 10.8%. What really drove that was volume – global medicine sales volume jumped 12.6%.

This performance has management feeling confident enough to bump up its 2030 revenue target to €10 billion. A big part of the story seems to be international expansion, especially in the U.S. market, where revenue surged 38.4% to hit €879 million.

While Servier remains a leader in cardio-metabolic conditions, it's clearly making strategic moves to beef up its presence in oncology and neurology.